Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist

scientific article published on 07 February 2017

Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1083720050
P356DOI10.1186/S13027-017-0119-8
P932PMC publication ID5297093
P698PubMed publication ID28191032

P50authorAlessandro PerrellaQ45468143
P2093author name stringA Lanza
A Nappi
C Sbreglia
A Izzi
P Bellopede
M Spatarella
P2860cites workGlobal epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalenceQ29616009
Diagnosis, management, and treatment of hepatitis C: an updateQ29619682
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002Q29619974
Hepatitis C virus infection trends in ItalyQ35819921
The changing epidemiology of hepatitis C virus infection in EuropeQ37006042
Novel therapies for hepatitis C: insights from the structure of the virusQ37937583
Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.Q38530211
Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapyQ38703524
Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or olderQ40171094
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C.Q41728099
APASL consensus statements and recommendation on treatment of hepatitis C.Q42400012
Prevention of hepatitis C in Italy: lessons from surveillance of type-specific acute viral hepatitisQ62579354
Myo-pericarditis secondary to ledipasvir-sofosbuvir therapyQ87155509
P407language of work or nameEnglishQ1860
P304page(s)12
P577publication date2017-02-07
P1433published inInfectious Agents and CancerQ15814259
P1476titleSafety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist
P478volume12

Reverse relations

cites work (P2860)
Q41108422Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study
Q58698597Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection

Search more.